[go: up one dir, main page]

ME01507B - Imidazotriazini i imidazopirimidini kao inhibitori kinaze - Google Patents

Imidazotriazini i imidazopirimidini kao inhibitori kinaze

Info

Publication number
ME01507B
ME01507B MEP-2013-35A MEP3513A ME01507B ME 01507 B ME01507 B ME 01507B ME P3513 A MEP3513 A ME P3513A ME 01507 B ME01507 B ME 01507B
Authority
ME
Montenegro
Prior art keywords
imidazo
quinolin
ylcyclopropyl
pyrimidin
benzamide
Prior art date
Application number
MEP-2013-35A
Other languages
English (en)
Inventor
Jincong Zhuo
Brian Metcalf
Meizhong Xu
Chunhong He
Colin Zhang
Ding-Quan Qian
David M Burns
Yunlong Li
Wenqing Yao
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39166437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME01507(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Publication of ME01507B publication Critical patent/ME01507B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (66)

1.Spoj formule 1: ili njegova farmaceutski prihvatljiva sol ili njegov predlijek, naznačeni time da: A je N ili CR3; i (a) pri čemu, kada A je N; Cy1 je aril, heteroaril, cykloalkil, ili heterocikloalkil, svaki izborno zamijenjen s 1, 2, 3, 4 ili 5 -W-X-Y-Z; Cy2 je aril, heteroaril, cikloalkil, ili heterokicloalkil, svaki izborno zamijenjen s 1, 2, 3, 4 ili 5 -W’-X’-Y’-Z’; L1 je CH2, CH2CH2, cikloalkilen, O ili S L2 je (CR7R8)r, (CR7R8)s-(cikloalkilen)-(CR7R8)t, (CR7R8)s-(arilen)-(CR7R8)t, (CR7R8)s-(heteroci- kloalkilen)-(CR7R8)t, (CR7R8)s-(heteroarilen)-(CR7R8)t, (CR7R8)sO(CR7R8)t, (CR7R8)sS(CR7R8)t, (CR7R8)sC(O)(CR7R8)t, (CR7R8)sC(O)NR9(CR7R8)t, (CR7R8)sC(O)O(CR7R8)t, (CR7R8)sOC(O)(CR7R8)t, (CR7R8)sOC(O)NR9(CR7R8)t, (CR7R8)sNR9(CR7R8)t, (CR7R8)sNR9C(O)NR9(CR7R8)t, (CR7R8)sS(O) (CR7R8)t, (CR7R8)sS(O)NR7(CR8R9)t, (CR7R8)sS(O)2(CR7R8)t, or (CR7R8)sS(O)2NR9(CR7R8)t, pri čemu je navedeni cikloalkilen, arilen, heterocikloalkilen, ili heteroarilen izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od Cy4, halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, N3, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(=NRg)NRc1Rd1, NRc1C(=NRg)NRc1Rd1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2Rb1, i S(O)2NRc1Rd1; R1 je H ili ⎯W"-X"-Y"-Z"; R2 je H, halo, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, CN, NO2, ORA, SRA, C(O)RB, C(O)NRCRD, C(O)ORA, OC(O)RB, OC(O)NRCRD, NRCRD, NRCC(O)RB, NRCC(O)NRCRD, NRCC(O)ORA, S(O)RB, S(O)NRCRD, S(O)2RB, NRCS(O)2RB ili S(O)2NRCRD; R3 je H, cikloalkil, aril, heterocikloalkil, heteroaril, halo, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, CN, NO2, ORA, SRA, C(O)RB, C(O)NRCRD, C(O)ORA, OC(O)RB, OC(O)NRCRD, NRCRD, NRCC(O)RB, NRCC(O)NRCRD, NRCC(O)ORA, S(O)RB, S(O)NRCRD, S(O)2RB, NRCS(O)2RB i S(O)2NRCRD; gdje je navedeni cikloalkil, aril, heterocikloalkil, heteroaril ili C1-6 alkil izborno zamijenjen s 1,2 ili 3 supstituenta nezavisno odabrana od Cy5, halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, N3, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(=NRg)NRc1Rd1, NRc1C(=NRg)NRc1Rd1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2Rb1 i S(O)2NRc1Rd1; ili R2 i ⎯L2-Cy2 su povezani zajedno kako bi formirali skupinu formule: pri čemu je prsten B fuzionirani arilni ili fuzionirani heteroarilni prsten, svaki izborno zamijenjen s 1, 2 ili 3 -W’-X’-Y’-Z’; R4 je nezavisno odabran od H, halo, OH, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 alkoksija, alkoksialkila, cianoalkila, heterocikloalkila, cikloalkila, C1-6 haloalkila, CN, i NO2; R7 i R8 su nezavisno odabrani od H, halo, OH, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 alkoksija, C1-6 haloalkila, CN i NO2; ili R7 i R8 zajedno s C atomom za koji su povezani formiraju 3, 4, 5, 6 ili 7-člani cikloalkilni ili heterocikloalkilni prsten, svaki izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od halo, OH, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 alkoksija, C1-6 haloalkila, CN i NO2; R9 je H, C1-6 alkila, C2-6 alkenila ili C2-6 alkinila; W, W’ i W" su nezavisno odsutni ili nezavisno odabrani od C1-6 alkilena, C2-6 alkenilena, C2-6 alkinilena, O, S, NRh, CO, COO, CONRh, SO, SO2, SONRh i NRhCONRi, pri čemu je svaki od C1-6 alkilena, C2-6 alkenilena i C2-6 alkinilena izborno zamijenjen s 1, 2 ili 3 supstituenta odabrana od halo, C1-6 alkila, C1-6 haloalkila, OH, C1-6 alkoksija, C1-6 haloalkoksija, amina, C1-6 alkilamina i C2-8 dialkilamina; X, X’ i X" su nezavisno odsutni ili nezavisno odabrani od C1-6 alkilena, C2-6 alkenilena, C2-6 alkinilena, arilena, cikloalkilena, heteroarilena i heterocikloalkilena, pri čemu svaki od C1-6 alkilena, C2-6 alkenilena, C2-6 alkinilena, arilena, cikloalkilena, heteroarilena i heterocikloalkilena je izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od halo, CN, NO2, OH, C1-6 alkila, C1-6 haloalkila, C2-8 alkoksialkila, C1-6 alkoksija, C1-6 haloalkoksija, C2-8 alkoksialkoksija, cikloalkila, heterocikloalkila, C(O)ORj, C(O)NRhRi, amina, C1-6 alkilamina i C2-8 dialkilamina; Y, Y’ i Y" su nezavisno odsutni ili nezavisno odabrani od C1-6 alkilena, C2-6 alkenilena, C2-6 alkinilena, O, S, NRh, CO, COO, CONRh, SO, SO2, SONRh, i NRhCONRi, pri čemu je svaki od C1-6 alkilena, C2-6 alkenilena i C2-6 alkinilena izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od halo, C1-6 alkila, C1-6 haloalkila, OH, C1-6 alkoksija, C1-6 haloalkoksija, amina, C1-6 alkilamina i C2-8 dialkilamina; Z, Z’ i Z" su nezavisno odabrani od H, halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NR9)NRc2Rd2, NRc2C(=NR9)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O)ORe2ORf2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2, S(O)2NRc2Rd2, arila, cikloalkila, heteroarila i heterocikloalkila, gdje su navedeni C1-6 *alkil, C2-6 alkenil, C2-6 alkinil, aril, cikloalkil, heteroaril i heterocikloalkil izborno zamijenjeni s 1, 2, 3, 4 ili 5 supstituenta nezavisno odabrana od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NRg)NRc2Rd2, NRc2C(=NRg)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O)ORe2ORf2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2 , NRc2S(O)2Rb2 i S(O)2NRc2Rd2; pri čemu dva susjedna ⎯W-X-Y-Z, zajedno s atomima s kojima su povezani, izborno formiraju fuzionirani cikloalkilni prsten od 4-20 članova ili fuzionirani heterocikloalkilni prsten od 4-20 članova, svaki izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)NRc3Rd3, NRc3C(O)ORa3, C(=NRg)NRc3Rd3, NRc3C(=NRg)NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, NRc3S(O)2Rb3, S(O)2NRc3Rd3, arila, cikloalkila, heteroarila i heterocikloalkila; pri čemu dva susjedna ⎯W’-X’-Y’-Z’, zajedno s atomima s kojima su povezani, izborno formiraju fuzionirani cikloalkilni prsten od 4-20 članova ili spojeni heterocikloalkilni prsten od 4-20 članova, svaki izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, NRc3Rd3 , NRc3C(O)Rb3, NRc3C(O)NRc3Rd3, NRc3C(O)ORa3, C(=NRg)NRc3Rd3, NRc3C(=NRg)NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, NRc3S(O)2Rb3, S(O)2NRc3Rd3, arila, cikloalkila, heteroarila i heterocikloalkila; Cy4 i Cy5 su nezavisno odabrani od arila, cikloalkila, heteroarila i heterocikloalkila, svaki izborno zamijenjen s 1, 2, 3, 4 ili 5 supstituenta nezavisno odabrana od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, N3, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRg)NRc4Rd4, NRc4C(=NRg)NRc4Rd4, P(Rf4)2, P(OR4)2, P(O)Re4Rf4, P(O)ORe4ORf4, S(O)b4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4 i S(O)2NRc4Rd4; RA je H, C1-4 alkil, C2-4 alkenil, C2-4 alkinil, cikloalkil, heterocikloalkil, aril ili heteroaril gdje je navedeni C1-4 alkil, C2-4 alkenil, C2-4 alkinil, cikloalkil, heterocikloalkil, aril ili heteroaril izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo i C1-4 alkila; RB je H, C1-4 alkil, C2-4 alkenil, C2-4 alkinil, cicloalkil, heterocikloalkil, aril, ili heteroaril gdje je navedeni C1-4 alkil, C2-4 alkenil, ili C2-4 alkinil, cikloalkil, heterocikloalkil, aril, ili heteroaril izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo i C1-4 alkila; RC i RD su nezavisno odabrana od H, C1-4 alkila, C2-4 alkenila, ili C2-4 alkinila, gdje je navedeni C1-4 alkil, C2-4 alkenil, ili C2-4 alkinil izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo i C1-4 alkila; ili RC i RD zajedno s N atomom s kojim su povezani formiraju 4-, 5-, 6- ili 7-članu heterocikloalkilnu skupinu ili heteroarilnu skupinu, svaku izborno zamijenjenu s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo i C1-4 alkila; Ra, Ra1, Ra2, Ra3, i Ra4 su nezavisno odabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, heteroarila, heterocikloalkila, arilalkila, heteroarilalkila, cikloalkilalkila i heterocikloalkilalkila, gdje je navedeni C1-6 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, cikloalkil, heteroaril, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil, ili heterocikloalkilalkil izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila i C1-6 haloalkoksija; Rb, Rb1, Rb2, Rb3 i Rb4 su nezavisno odabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, heteroarila, heterocikloalkila, arilalkila, heteroarilalkila, cikloalkilalkila i heterocikloalkilalkila, pri čemu je navedeni C1-6 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alknil, aril, cikloalkil, heteroaril, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil ili heterocikloalkilalkil izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila i C1-6 haloalkoksija; Rc i Rd su nezavisno odabrani od H, C1-10 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, heteroarila, cikloalkila, heterocikloalkila, arilalkila, heteroarilalkila, cikloalkilalkila ili heterocikloalkilalkila, pri čemu je navedeni C1-10 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, heteroaril, cikloalkil, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil ili heterocikloalkilalkil izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila i C1-6 haloalkila; ili Rc i Rd zajedno s N atomom s kojim su povezani formiraju 4-, 5-, 6- ili 7-članu heterocikloalkilnu skupinu ili heteroarilnu skupinu, svaku izborno zamijenjenu s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila i C1-6 haloalkoksija; Rc1 i Rd1 su nezavisno odabrani od H, C1-10 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, heteroarila, cicloalkila, heterocikloalkila, arilalkila, heteroarilalkila, cikloalkilalkila ili heterocikloalkilalkila, pri čemu je navedeni C1-10 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, heteroaril, cikloalkil, heterocikloalkil, arilalkil, heteroarilalkil, cicloalkilalkil ili heterocicloalkilalkil izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila, i C1-6 haloalkoksija; ili Rc1 i Rd1 zajedno s N atomom s kojim su povezani formiraju 4-, 5-, 6- ili 7-članu heterocikloalkilnu skupinu ili heteroarilnu skupinu, svaku izborno zamijenjenu s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila i C1-6 haloalkoksija; Rc2 i Rd2 su nezavisno odabrani od H, C1-10 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, heteroarila, cikloalkila, heterocikloalkila, arilalkila, heteroarilalkila, cikloalkilalkila, heterocikloalkilalkila, arilcikloalkila, arilheterocikloalkila, arilheteroarila, biarila, heteroarilcikloalkila, heteroarilheterocikloalkila, heteroarilarila i biheteroarila, pri čemu je navedeni C1-10 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, heteroaril, cikloalkil, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil, heterocikloalkilalkil, arilcikloalkil, arilheterocikloalkil, arilheteroaril, biaril, heteroarilcikloalkil, heteroarilheterocikloalkil, heteroarilaril i biheteroaril svaki izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila, C1-6 haloalkoksija, hidroksialkila, cianoalkila, arila, heteroarila, C(O)ORa4, C(O)Rb4, S(O)2Rb3,alkoksialkila i alkoksialkoksija; ili Rc2 ili Rd2 zajedno sa N atomom s kojim su povezani formiraju 4-, 5-, 6- ili 7-članu heterocikloalkilnu skupinu ili heteroarilnu skupinu, svaku izborno zamijenjenu s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila, C1-6 haloalkoksija, hidroksialkila, cianoalkila, arila, heteroarila, C(O)ORa4, C(O) Rb4, S(O)2Rb3, alkoksialkila i alkoksialkoksija; Rc3 i Rd3 su nezavisno odabrani od H, C1-10 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, heteroarila, cikloalkila, heterocikloalkila, arilalkila, heteroarilalkila, cikloalkilalkila ili heterocikloalkilalkila, pri čemu je navedeni C1-10 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, heteroaril, cikloalkil, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil ili heterocikloalkilalkil izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila i C1-6 haloalkoksi; ili Rc3 i Rd3 zajedno s N atomom s kojim su povezani formiraju 4-, 5-, 6- ili 7-članu heterocikloalkilnu skupinu ili heteroarilnu skupinu, svaku izborno zamijenjenu s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila i C1-6 haloalkoksija; Rc4 i Rd4 su nezavisno odabrani od H, C1-10 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, heteroarila, cikloalkila, heterocikloalkila, arilalkila, heteroarilalkila, cikloalkilalkila ili heterocikloalkilalkila, pri čemu je navedeni C1-10 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, heteroaril, cikloalkil, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil ili heterocikloalkilalkil izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila, i C1-6 haloalkoksija; ili Rc4 i Rd4 zajedno sa N atomom s kojim su povezani formiraju 4-, 5-, 6- ili 7-članu heterocikloalkilnu skupinu ili heteroarilnu skupinu, svaku izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila i C1-6 haloalkoksija; Re, Re1, Re2 i Re4 su nezavisno odabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, (C1-6 alkoksi)-C1-6 alkila, C2-6 alkinila, arila, cikloalkila, heteroarila, heterocikloalkila, arilalkila, cikloalkilalkila, heteroarilalkila i heterocikloalkilalkila; Rf, Rf1, Rf2 i Rf4 su nezavisno odabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, heteroarila i heterocikloalkila; Rg je H, CN i NO2; Rh i Ri su nezavisno odabrani od H i C1-6 alkila; Rj je H, C1-6 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, cikloalkil, heteroaril, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil ili heterocikloalkilalkil; r je 0, 1, 2, 3, 4, 5 ili 6; s je 0, 1, 2, 3 ili 4; i t je 0, 1, 2, 3 ili 4; i (b) pri čemu, kada je A CR3: L’ je cikloalkilen, O ili S; a sve druge varijable su definirane kao pod (a)
2.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da A jest N.
3.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da A jest CR3.
4.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da A jest CH.
5.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy1 jest aril ili heteroaril, svaki izborno zamijenjen s 1, 2, 3, 4 ili 5 -W-X-Y-Z.
6.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy1 jest aril izborno zamijenjen s 1, 2, 3, 4 ili 5 -W-X-Y-Z.
7.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time da Cy1 jest heteroaril izborno zamijenjen s 1, 2, 3, 4 ili 5 -W-X-Y-Z.
8.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy1 jest kinonlinil izborno zamijenjen s 1, 2, 3, 4 ili 5 -W-X-Y-Z.
9.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy1 jest kinolinil.
10.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy2 jest aril ili heteroaril, svaki izborno zamijenjen s 1, 2, 3, 4 ili 5 -W’-X’-Y’-Z’.
11.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy2 jest aril ili heteroaril, svaki izborno zamijenjen s 1, 2, 3, 4 ili 5 -W’-X’-Y’-Z’ pri čemu najmanje jedan od navedenih -W’-X’-Y’-Z’ je C(O)NRc2Rd2.
12.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy2 jest aril izborno zamijenjen s 1, 2, 3, 4 ili 5 -W’-X’-Y’-Z’.
13.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy2 jest heteroaril izborno zamijenjen s 1, 2, 3, 4 ili 5 -W’-X’-Y’-Z’.
14.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L1 jest O ili S.
15.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L1 jest CH2 ili CH2CH2 ili cikloalkilen.
16.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L1 jest CH2 ili ciklopropilen.
17.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L1 jest cikloalkilen.
18.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L1 jest ciklopropilen.
19.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L2 jest (CR7R8)r.
20.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L2 jest (CR7R8)r i r je 0.
21.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L2 jest (CR7R8)r, (CR7R8)s-(cikloalkilen)-(CR7R8)t, (CR7R8)s-(arilen)-(CR7R8)t,(CR7R8)s-(heterocikloalkilen)-(CR7R8)t ili (CR7R8)s-(heteroarilen)-(CR7R8)t, gdje je navedeni cikloalkilen, arilen, heterocikloalkilen ili heteroarilen izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od Cy4, halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, N3, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(=NRg)NRc1Rd1, NRc1C(=NRg)NRc1Rd1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORelORfi, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2Rb1, i S(O)2NRc1Rd1.
22.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L2 jest (CR7R8)r, (CR7R8)s-(cikloalkilen)-(CR7R8)t ili (CR7R8)-(arilen)-(CR7R8)t, gdje je navedeni cikloalkilen ili arilen izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od Cy4, halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, N3, ORa1, SRa1, C(O)Rb1, C(O)NRclRad1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(=NRg)NRc1Rd1, NRc1C(=NRg)NRc1Rd1, P(Rf1)2, P(ORe1)2,P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2Rb1 i S(O)2NRc1Rd1.
23.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L2 jest (CR7R8)s-(cikloalkilen)-(CR7R8)t ili (CR7R8)s-(arilen)-(CR7R8)t, gdje je navedeni cikloalkilen ili arilen izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od Cy4, halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, N3, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(=NRg)NRc1Rd1, NRc1C(=NRg)NRc1Rd1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1. P(O)ORe1ORf1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2 Rb1 i S(O)2NRc1Rd1.
24.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L2 jest cikloalkilen ili arilen.
25.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L2 jest arilen.
26.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy2 jest aril izborno zamijenjen s 1, 2, 3, 4 ili 5 -W’-X’-Y’-Z’.
27.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy2 jest heteroaril izborno zamijenjen s 1, 2, 3, 4 ili 5 -W’-X’-Y’-Z’.
28.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy2 jest cikloalkil izborno zamijenjen s 1, 2, 3, 4 ili 5 -W’-X’-Y’-Z’.
29.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy2 jest heterocikloalkil izborno zamijenjen s 1, 2, 3, 4 ili 5 -W’-X’-Y’-Z’.
30.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da R1 jest H.
31.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da R2 jest H.
32.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da R3 jest H.
33.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da R4 jest H.
34.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da R7 jest H.
35.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da R8 jest H.
36.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da R9 jest H.
37.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da -W-X-Y-Z jest halo, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, halosulfanil, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NRg)NRc2Rd2, NRc2C(=NRg)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O)ORe2ORf12, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2, S(O)2NRc2Rd2, aril, cikloalkil, heteroaril i heterocicloalkil, pri čemu je navedeni C1-6 alkil, C2-6 alkenil, C2-6 alkinil, aril, cikloalkil, heteroaril i heterocikloalkil izborno zamijenjen s 1, 2, 3, 4 ili 5 supstituenta nezavisno odabrana od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NRg)NRc2Rd2, NRc2C(=NRg)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O)ORe2ORf2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2,NRc2S(O)2Rb2 i S(O)2NRc2Rd2.
38.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da -W-X-Y-Z jest halo, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, halosulfanil, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NRg)NRc2Rd2, NRc2C(=NRg)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O)ORe2ORf2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2 ili S(O)2NRc2Rd2.
39.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da -W-X-Y-Z jest halo, C1-6 alkil, C1-6 haloalkil, CN, NO2, N3 ili ORa2.
40.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da –W-X-Y-Z jest ORa2.
41.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da –W-X-Y-Z jest metoksi.
42.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da – W’-X’-Y’-Z’ jest halo, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, halosulfanil, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NRg)NRc2Rd2, NRc2C(=NRg)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O)ORe2ORf2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2, S(O)2NRc2Rd2, aril, cikloalkil, heteroaril i heterocikloalkil, pri čemu je navedeni C1-6 alkil, C2-6 alkenil, C2-6 alkinil, aril, cikloalkil, heteroaril i heterocikloalkil izborno zamijenjen sa 1, 2, 3, 4 ili 5 supstituenta nezavisno odabrana od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NRg)NRc2Rd2, NRc2C(=NRg)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O)ORe2ORf2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2 i S(O)2NRc2Rd2.
43.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da –W’-X’-Y’-Z’ jest halo, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, halosulfanil, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NRg)NRc2Rd2, NRc2C(=NRg)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O)ORe2ORf2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2 ili S(O)2NRc2Rd2.
44. Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da –W’-X’-Y’-Z’jest halo, C1-6 alkil, C1-6 haloalkil, CN, NO2, N3, ORa2 ili C(O)NRc2Rd2
45.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da -W’-X’-Y’-Z’ jest halo, C1-6 alkil, C1-6 haloalkil, CN, NO2, N3 ili ORa2.
46.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da -W’-X’-Y’-Z’ jest halo ili C(O)NRc2Rd2.
47.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da imaju formulu IIa ili IIb:
48.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da imaju formulu III:
49.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da imaju formulu VIII:
50.Spoj prema zahtjevu 1, naznačen time da je odabran od: 2-(4-fluorofenil)-7-(4-metoksibenzil)imidazo[1,2-b] [1,2,4]triazina; 2-(4-fluorofenil)-7-[1-(4-metoksifenil)ciklopropil]imidazo[1,2-b]-[1,2,4]-triazina; 6-(1-(2-(4-fluorofenil)imidazo[1,2-b][1,2,4]triazin-7-il)ciklopropil)kinolina; 6-(4-fluorofenil)-3-(4-metoksibenzil)imidazo[1,2-a]pirimidina; 6-(4-fluorofenil)-3-(1-(4-metoksifenil)ciklopropil)imidazo[1,2-a]pirimidina; 6-(1-(6-(4-fluorofenil)imidazo[1,2-a]pirimidin-3-il)ciklopropil)kinolina; 2-fluoro-N-metil-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-(4-bromo-3-fluorofenil)-7-[(4-metoksifenil)tio]imidazo[1,2-b][1,2,4]triazina; 2-fluoro-4-(3-[(4-metoksifenil)tio]imidazo[1,2-a]pirimidin-6-il)-N-metilbenzamida; 2-kloro-4-3-[(4-metoksifenil)tio]imidazo[1,2-a]pirimidin-6-il-N-metilbenzamida; 2-fluoro-N-metil-4-[3-(kinolin-6-ltio)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-kloro-N-metil-4-[3-(kinolin-6-iltio)imidazo[1,2-a]pirimidin-6-il]benzamida; metil-2-fluoro-4-[7-(kinolin-6-iltio)imidazo[1,2-b][1,2,4]triazin-2-il]benzoata; 2-(4-bromo-3-fluorofenil)-7-(4-metoksifenoksi)imidazo[1,2-b][1,2,4]triazina; 3-(4-metoksifenoksi)-6-(4-metil-1H-pirazol-1-il)imidazo[1,2-a]pirimidina; 6-(4-bromofenil)-3-(4-metoksifenoksi)imidazo[1,2-a]pirimidina; 2-kloro-N-metil-4-[3-(kinolin-6-iloksi)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-fluoro-N-metil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 6-(4-bromofenil)-3-[(4-metoksifenil)tio]imidazo[1,2-a]pirimidina; 2-(4-fluorofenil)-7-[(4-metoksifenil)tio]imidazo[1,2-b][1,2,4]triazina; 6-(1-{6-[3-fluoro-4-(1-metil-2-okso-2-pirolidin-1-iletoksi)fenil]imidazo[1,2-a]pirimidin-3-il}ciklopropil)kinolina; 6-{1-[6-(1H-pirazol-1-il)imidazo[1,2-a]pirimidin-3-il]ciklopropil}kinolina; 6-1-[6-(4-metil-1H-pirazol-1-il)imidazo[1,2-a]pirimidin-3-il]ciklopropil}kinolina; N,N-dimetil-1-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]-1H-pirazol-4-karboksamida; N-[1-(4-metil-1,3-tiazol-2-il)etil]-1-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]-1H-pirazol-4-karboksamida; N-cikloheksil-3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-karboksamida; 3-(1-kinolin-6-ilciklopropil)-N-(tetrahidrofuran-2-ilmetil)imidazo[1,2-a]pirimidin-6-karboksamida; N-ciklobutil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 6-(1-{16-[4-(azetidin-1-ilkarbonil)fenil]imidazo[1,2-a]pirimidin-3-il}ciklopropil)kinolina; N,N-dimetil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]-N-(tetrahidrofuran-2-ilmetil)benzamida; N-(1-benzilpirolidin-3-il)-N-metil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-(1-piridin-2-ilpiperidin-4-il)-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-(1-piridin-2-iletil)-4-[3-(1-kinolin-6-ilcilopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 6-{1-[6-(4-[(3S)-3-fluoropirolidin-1-il]karbonilfenil)imidazo[1,2-a]pirimidin-3-il]ciklopropil}kinolina; N-[1-(metoksimetil)ciklobutil]-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-(1-piridin-2-ilpirolidin-3-il)-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 6-[1-(6-{4-[(3-piridin-2-ilpirolidin-1-il)karbonil]fenil}imidazo[1,2-a]pirimidin-3-il)ciklopropil]kinolina; 6-{1-[6-(4-[(3S)-3-(piridin-2-iloksi)pirolidin-1-il]karbonilfenil)imidazo[1,2-a]pirimidin-3-il]ciklopropil}kinolina; N-[2-(piridin-2-iloksi)etil]-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-[1-metil-2-(piridin-2-iloksi)etil]-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-(2-fenoksietil)-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamid; N-(1S)-2,2-dimetil-1-[(metilamino)karbonil]propil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-(1S)-1-[(dimetilamino)karbonil]-2,2-dimetilpropil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-[(1S)-1-(azetidin-1-ilkarbonil)-2,2-dimetilpropil]-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-ciklopropil-3-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-(piridin-2-ilmetil)-3-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N,N-dimetil-3-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-metil-3-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-[(1S)-1-metil-2-(metilamino)-2-oksoetil]-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-[(1R)-1-metil-2-(metilamino)-2-oksoetil]-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; (3R)-1-{4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzoil}pirolidin-3-karbonitrila; metil-4-{5-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]piridin-2-il}-piperazin-1-karboksilata; 6-[1-(6-{6-[4-(metilsulfonil)piperazin-1-il]piridin-3-il}imidazo[1,2-a]pirimidin-3-il)ciklopropil]kinolina; N,N-dimetil-4-{5-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]piridin-2-il}piperazin-1-karboksamida; N-(1S)-1-[(dimetilamino)karbonil]-2-metilpropil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-1-[(dimetilamino)karbonil]ciklobutil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-[(1S)-1-(azetidin-1-ilkarbonil)-2,2-dimetilpropil]-5-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]piridin-2-karboksamida; N-(1S)-2,2-dimetil-1-[(metilamino)karbonil]propil-5-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]piridin-2-karboksamida; N-(1S)-1-[(ciklopropilamino)karbonil]-2,2-dimetilpropil-5-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]piridin-2-karboksamida; N-[(1S)-2-(dimetilamino)-1-metil-2-oksoetil]-5-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]piridin-2-karboksamida; N-[(1R)-2-(dimetilamino)-1-metil-2-oksoetil]-5-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]piridin-2-karboksamida; 6-(1-{6-[4-(2-okso-2-pirolidin-1-iletoksi)fenil]imidazo[1,2-a]pirimidin-3-il}ciklopropil)kinolina; 1-{4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]fenil}ciklopropankarbonitrila; N,N-dimetil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzensulfonamida; metil-2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzilkarbamata; N’-2-fluoro-4[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzil-N,N-dimetiluree; (3R)-1-{2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzil}pirolidin-3-ola; 6-(1-{6-[3-fluoro-4-(1H-pirazol-1-ilmetil)fenil]imidazo[1,2-a]pirimidin-3-il}ciklopropil)kinolina; 3-{2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzil}-1,3-oksazolidin-2-ona; 2-fluoro-N-metil-4-[7-(kinoksalin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 6-{1-[6-(4-kloro-1H-pirazol-1-il)imidazo[1,2-a]pirimidin-3-il]ciklopropil}kinolina; 6-{1-[6-(2-metil-1,3-tiazol-4-il)imidazo[1,2-a]pirimidin-3-il]ciklopropil} kinolina; 6-{1-[6-(1,3-tiazol-4-il)imidazo[1,2-a]pirimidin-3-il]ciklopropil}kinolina; 3-fluoro-N-metil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; (3S)-1-{3-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzoil}pirolidin-3-ola; 2,5-difluoro-N-metil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2,5-difluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-ciklopropil-2,5-difluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2,5-difluoro-N-(trans-4-hidroksicikloheksil)-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 1-{2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]fenil}pirolidin-2-ona; 3-{2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]fenil}-1,3-oksazolidin-2-ona; etil-4-{4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]-1H-pirazol-1-il}piperidin-1-karboksilata; 2-(4-{2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]fenil}-1H-pirazol-1-il)-N,N-dimetilacetamida; 5-{2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]fenil}-N-metilpiridin-2-karboksamida; 5-{2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]fenil}-N,N-dimetilpiridin-2-karboksamida; 6-(1-{6-[3-fluoro-4-(1-metil-1H-pirazol-4-il)fenil]imidazo[1,2-a]pirimidin-3-il}ciklopropil)kinolina; 6-(1-{6-[1-(fetrahidrofuran-3-il)-1H-pirazol-4-il]imidazo[1,2-a]pirimidin-3-il}ciklopropil)kinolina; 6-(1-{6-[1-(1-benzilpirolidin-3-il)-1H-pirazol-4-il]imidazo[1,2-a]pirimidin-3-il}ciklopropil)kinolina; 6-{1-[6-(1-metil-1H-pirazol-4-il)imidazo[1,2-a]pirimidin-3-il]ciklopropil}kinolina; N,N-dimetil-4-{4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]-1H-pirazol-1-il}piperidin1-karboksamida; 4-{4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]-1H-pirazol-1-il}cikloheksanola; {4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]-1H-pirazol-1-il} acetonitrila; N-metil-5-{4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]fenil}piridin-2-karboksamida; 6-{1-[2-(4-pirimidin-5-il-fenil)imidazo[1,2-b][1,2,4]triazin-7-il]ciklopropil}kinolina; 6-(1-{2-[4-(1-acetil-1,2,3,6-tetrahidropiridin-4-il)fenil]imidazo[1,2-b][1,2,4]triazin-7-il}ciklopropil)kinolina; 6-[1-(2-(4-[1-(metilsulfonil)-1,2,3,6-tetrahidropiridin-4-il]fenil}imidazo[1,2-b][1,2,4]triazin-7-il)ciklopropil]kinolina; N,N-dimetil-5-{4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]fenil}piridin-2-karboksamida; 6-(1-{2-[4-(1H-imidazol-1-il)fenil]imidazo[1,2-b][1,2,4]triazin-7-il}ciklopropil)-kinolina; 2-fluoro-N-(trans-4-hidroksicikloheksil)-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-ciklopropil-2-fluoro-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-metil-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-[1-(metoksimetil)ciklopropil]-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-4-(7-(1-(kinolin-6-il)ciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il)benzamida; 4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]-N-(tetrahidrofuran-2-ilmetil)benzamida; N-(piridin-2-ilmetil)-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-ciklopropil-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-ciklobutil-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-(1-piridin-2-ilciklopropil)-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-(2-hidroksi-1,1-dimetiletil)-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-[(1S)-1-benzil-2-hidroksietil]-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; (3R)-1-{4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzoil}pirolidin-3-ola; 4-(7-(1-(kinolin-6-il)ciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il)-N-(tetrahidro-2H-piran-4-il)benzamida; N-ciklopropil-N-metil-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-[1-(metoksimetil)ciklopropil]-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-[1-(metoksimetil)ciklobutil]-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-[(1S)-1-(metoksimetil)-2-metilpropil]-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-[4-(metoksimetil)tetrahidro-2H-piran-4-il]-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]-N-1,3-tiazol-2-ilbenzamida; N-pirimidin-4-il-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-[4-(metoksimetil)tetrahidro-2H-piran-4-il]-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-ciklopropil-2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-[1-(metoksimetil)ciklopropil]-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]-N-(tetrahidro-2H-piran-4-il)benzamida; (3R)-1-{2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzoil}pirolidin-3-ola; 2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-(trans-4-hidroksicikloheksil)-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 6-{2-[3-fluoro-4-(1H-imidazol-1-il)fenil]imidazo[1,2-b][1,2,4]triazin-7-ilmetil}kinolina; 3-{2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]fenil}-1,3-oksazolidin-2-ona; N-(1S)-2,2-dimetil-1-[(metilamino)karbonil]propil-2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-(1S)-1-[(dimetilamino)karbonil]-2,2-dimetilpropil-2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b] [1,2,4]triazin-2-il]benzamida; N-[(1S)-1-(azetidin-1-ilkarbonil)-2,2-dimetilpropil]-2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-{(1S)-1-[(dimetilamino)karbonil]-3-metilbutil-2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-{(1R)-3-metil-1-[(metilamino)karbonil]butil}-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-{(1R)-1-[(dimetilamino)karbonil]-3-metilbutil}-2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-[(1R)-1-(azetidin-1-ilkarbonil)-3-metilbutil]-2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4] triazin-2-il]benzamida; 3-{4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]-1H-pirazol-1-il} propanenitrila; 4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]-1H-pirazol-1-ilacetonitrila; 2-{4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]-1H-pirazol-1-il}acetamida; metil-4-{4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]-1H-pirazol-1-il}piperidin-1-karboksilata; 2-fluoro-N-[(1S,2S)-2-hidroksiciklopentil]-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-(2-hidroksietil)-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-[1-(metoksimetil)ciklobutil]-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-[4-(metoksimetil)tetrahidro-2H-piran-4-il]-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-(ciklopropilmetil)-2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]-N-(tetrahidro-2H-piran-4-ilmetil)benzamida; N-[2-(dimetilamino)etil]-2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-(2-piperidin-1-iletil)-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-[2-(1-metilpirolidin-2-il)etil]-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-(piridin-2-ilmetil)-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-(piridin-3-ilmetil)-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-(piridin-4-ilmetil)-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-(2-piridin-2-iletil)-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b] [1,2,4]triazin-2-il]benzamida; 2-fluoro-N-(1-piridin-3-iletil)-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-(1-piridin-4-iletil)-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-[(1S)-1-(hidroksimetil)-2,2-dimetilpropil]-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-[1-(hidroksimetil)ciklopentil]-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-(2-metoksi-1-metiletil)-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 6-{1-[6-(3-fluoro-4-[(3S)-3-fluoropirolidin-1-il]karbonilfenil)imidazo[1,2-a]pirimidin-3-il]ciklopropil} kinolina; 2-fluoro-N-(piridin-2-ilmetil)-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-fluoro-N-(1-piridin-2-ilciklopropil)-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-fluoro-N-(1-piridin-2-ilpirolidin-3-il)-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]-N-[(3R)-tetrahidrofuran-3-il]benzamida; 2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]-N-(tetrahidrofuran-2-ilmetil)benzamida; N-ciklopropil-2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-fluoro-N-[(1S)-1-(metoksimetil)-2-metilpropil]-4-[3-(1-kinolin-6-ilcklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-fluoro-N-metil-N-2-[metil(piridin-2-il)amino]etil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-kloro-N-metil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-kloro-N-ciklopropil-4[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-kloro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]-N-(tetrahidrofuran-3-il)benzamida; 2-kloro-N-(1-piridin-2-iletil)-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 6-(1-{6-[4-(Azetidin-1-ilkarbonil)-3-klorofenil]imidazo[1,2-a]pirimidin-3-il}ciklopropil)kinolina; 2-kloro-N-(1-piridin-2-ilpirolidin-3-il)-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-kloro-N-[1-metil-2-(piridin-2-iloksi)etil]-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-kloro-N-(1S)-1-[(dimetilamino)karbonil]-2-metilpropil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-ciklopropil-5-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]izoindolin-1-ona; 2-etil-5-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]izoindolin-1-ona; 2-(2-metoksi-1-metiletil)-S-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]izoindolin-1 -ona; 2-(piridin-2-ilmetil)-5-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]izoindolin-1-ona; 2-metil-5-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]izoindolin-1-ona; N-etil-1-{4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]fenil}ciklopropankarboksamida; N-(1-piridin-2-iletil)-1-{4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]fenil}ciklopropankarboksamida; N-[1-metil-2-(piridin-2-iloksi)etil]-1-{4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]fenil}ciklopropankarboksamida; 2-{2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]fenil}-2-hidroksi-N-metilacetamida; 2-{2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]fenil}-2-hidroksi-N,N-dimetilacetamida; N-(3-[2-(4-bromo-3-fluorofenil)imidazo[1,2-b][1,2,4]triazin-7-il]metilfenil)-N’-etiluree; 2-(2,3-dihlorofenil)-7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-3-amina; 2,3-difluoro-N-metil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 6-difluoro-N-metil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-fluoro-N-metil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzensulfonamida; N,N-dimetil-2-{3-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]-1H-pirazol-1-il}acetamida; N-[(1S)-1-(azetidin-1-ilkarbonil)-2,2-dimetilpropil]-2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-[2-(dimetilamino)-1-metil-2-oksoetil]-2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-(2-azetidin-1-il-1-metil-2-oksoetil)-2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-fluoro-N-2-[(3R)-3-metoksipirolidin-1-il]-1-metil-2-oksoetil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-fluoro-N-[(1-hidroksiciklopropil)metil]-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; metil-4-(cijanometil)-4-{4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]-1H-pirazol-1-il}piperidin-1-karboksilata; etil-4-(cijanometil)-4-{4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]-1H-pirazol-1-il}piperidin-1-karboksilata; (1-acetil-4-{4-[7-(kinolin-6-ilmetil)imidazo[1,2-b] [1,2,4]triazin-2-il]-1H-pirazol-1-il}piperidin-4-il)acetonitrila, ili njihovih farmaceutski prihvatljivih soli.
51.Spoj prema zahtjevu 1, naznačen time da je 2-fluoro-N-metil-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamid ili njegova farmaceutski prihvatljiva sol.
52.Sastav, naznačen time da sadrži spoj bilo kojeg zahtjeva od 1 do 51 ili njegovu farmaceutski prihvatljivu sol i najmanje jedan farmaceutski prihvatljivi nosač.
53.Sastav, naznačen time da sadrži spoj prema zahtjevu 51 ili njegovu farmaceutski prihvatljivu sol i najmanje jedan farmaceutski prihvatljivi nosač.
54.Metoda inhibiranja aktivnosti receptorske ili nereceptorske tirozin-kinaze ex vivo, naznačena time da uključuje dovođenje navedene kinaze u kontakt sa spojem iz bilo kojeg zahtjeva od 1 do 51 ili njegovom farmaceutski prihvatljivom soli.
55.Metoda prema zahtjevu 54, naznačena time da navedena kinaza pripada podfamiliji Met, PDGFR, HER, FLK, Src, Abl ili Jak.
56.Metoda prema zahtjevu 54, naznačena time da je navedena kinaza c-Met, Ron, PDGFR beta, c-kit, EGFR, HER2, KDR, flt-3, Src, Abl, Jak1, Jak2 ili Jak 3 kinaza.
57.Metoda prema zahtjevu 54, naznačena time da je navedena kinaza c-Met.
58.Metoda inhibiranja signalnog puta HGF/c-Met kinaze u stanici ex vivo, naznačena time da uključuje dovođenje navedene stanice u kontakt sa spojem iz bilo kojeg zahtjeva od 1 do 51 ili njegovom farmaceutski prihvatljivom soli.
59.Metoda inhibiranja proliferativne aktivnosti stanice ex vivo, naznačena time da uključuje dovođenje navedene stanice u kontakt sa spojem iz bilo kojeg zahtjeva od 1 do 51 ili njegovom farmaceutski prihvatljivom soli.
60.Spoj prema bilo kojem zahtjevu od 1 do 51 ili njegova farmaceutski prihvatljiva sol, naznačeni time da se upotrebljavaju u inhibiciji rasta tumora kod pacijenata.
61.Spoj prema bilo kojem zahtjevu od 1 do 51 ili njegova farmaceutski prihvatljiva sol, naznačeni time da se upotrebljavaju u inhibiciji metastaze tumora kod pacijenata.
62.Spoj prema bilo kojem zahtjevu od 1 do 51 ili njegova farmaceutski prihvatljiva sol, naznačeni time da se upotrebljavaju u liječenju bolesti kod pacijenta, gdje je navedena bolest povezana s nepravilnom regulacijom signalnog puta HGF/c-MET.
63.Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 62, naznačeni time da se upotrebljavaju u liječenju bolesti pri čemu je navedena bolest rak, ateroskleroza, plućna fibroza, renalna fibroza i regeneracija, bolest jetre, alergijski poremećaj, upalna bolest, autoimuni poremećaj, cerebrovaskularna bolest, kardiovaskularna bolest ili stanje povezano sa transplantacijom organa.
64.Spoj prema bilo kojem zahtjevu od 1 do 51 ili njegova farmaceutski prihvatljiva sol, naznačeni time da se upotrebljavaju u liječenju raka kod pacijenta.
65.Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 64, naznačeni time da se upotrebljavaju u liječenju raka pri čemu je navedeni rak karcinom, mišićnokoštani sarkom, sarkom mekog tkiva ili hematopoetski malignitet.
66.Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 64, naznačeni time da se upotrebljavaju u liječenju raka pri čemu je navedeni rak rak mokraćnog mjehura, rak dojke, rak grlića materice, kolangiokarcinom, rak debelog crijeva, rak jednjaka, rak želuca, rak glave i vrata, rak bubrega, rak jetre, rak pluća, nazofaringealni rak, rak jajnika, rak pankreasa, rak prostate, rak štitne žlijezde, osteosarkom, sinovijalni sarkom, rabdomiosarkom, MFH/fibrosarkom, leiomiosarkom, Kaposijev sarkom, multipli mijelom, limfom, leukemija odraslih T stanica, akutna mijelogena leukemija, kronična mijeloična leukemija, glioblastom, astrocitom, melanom, mezoteliom ili Wilmsov tumor. 1
MEP-2013-35A 2006-11-22 2007-11-19 Imidazotriazini i imidazopirimidini kao inhibitori kinaze ME01507B (me)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86084006P 2006-11-22 2006-11-22
US86145906P 2006-11-29 2006-11-29
US95723607P 2007-08-22 2007-08-22
EP07864592A EP2099447B1 (en) 2006-11-22 2007-11-19 Imidazotriazines and imidazopyrimidines as kinase inhibitors
PCT/US2007/085100 WO2008064157A1 (en) 2006-11-22 2007-11-19 Imidazotriazines and imidazopyrimidines as kinase inhibitors

Publications (1)

Publication Number Publication Date
ME01507B true ME01507B (me) 2014-04-20

Family

ID=39166437

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2013-35A ME01507B (me) 2006-11-22 2007-11-19 Imidazotriazini i imidazopirimidini kao inhibitori kinaze
MEP-2016-13A ME02372B (me) 2006-11-22 2007-11-19 Imidazotriazini i imidazopiramidini kao inhibitori kinaze

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2016-13A ME02372B (me) 2006-11-22 2007-11-19 Imidazotriazini i imidazopiramidini kao inhibitori kinaze

Country Status (36)

Country Link
US (8) US7767675B2 (me)
EP (4) EP3443958A1 (me)
JP (1) JP5572388B2 (me)
KR (2) KR101588583B1 (me)
CN (2) CN103288833B (me)
AR (1) AR066142A1 (me)
AU (1) AU2007323725B2 (me)
BR (1) BRPI0719333A2 (me)
CA (1) CA2669991C (me)
CL (1) CL2007003341A1 (me)
CO (1) CO6210810A2 (me)
CR (1) CR10841A (me)
CY (4) CY1116763T1 (me)
DK (3) DK2099447T3 (me)
EA (2) EA032254B1 (me)
EC (1) ECSP099400A (me)
ES (3) ES2689444T3 (me)
FR (1) FR22C1060I2 (me)
GE (1) GEP20125658B (me)
HR (3) HRP20130106T1 (me)
HU (2) HUE026659T2 (me)
IL (4) IL198716A (me)
LT (2) LT3034075T (me)
LU (1) LUC00293I2 (me)
ME (2) ME01507B (me)
MX (1) MX2009005144A (me)
MY (2) MY188335A (me)
NL (1) NL301209I2 (me)
NO (4) NO346024B1 (me)
NZ (1) NZ577127A (me)
PL (3) PL2099447T3 (me)
PT (3) PT2099447E (me)
RS (3) RS54510B1 (me)
SI (3) SI3034075T1 (me)
TW (1) TWI429432B (me)
WO (1) WO2008064157A1 (me)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE025173T2 (hu) 2005-12-13 2016-01-28 Incyte Corp Heteroaril-szubsztituált pirrollo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
DK2010493T3 (en) 2006-04-12 2016-05-02 Merck Sharp & Dohme PYRIDYLAMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS
US7683060B2 (en) * 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
SI3034075T1 (sl) * 2006-11-22 2018-12-31 Incyte Holdings Corporation Imidazotriazini in imidazopirimidini kot inhibitorji kinaze
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
CA2701594C (en) * 2007-10-24 2014-02-18 Merck Sharp & Dohme Corp. Heterocycle phenyl amide t-type calcium channel antagonists
AR070487A1 (es) 2008-02-28 2010-04-07 Novartis Ag Derivados de 3- metil- imidazo -( 1,2-b)- piridazina
CL2009001250A1 (es) 2008-05-21 2010-02-05 Sal del acido dihidroclorico y dibencensulfonico de 2-fluoro-n-metil-4-[7-(quinolin-6-ilmetil)imidazol[1,2-b][1,2,4]1,2,4]triazin-2-il]benzamida; compuestos intermediarios; procesos de preparacion; composicion farmaceutica; y uso para tratar cancer, aterosclerosis, fibrosis pulmonar, enfermedad renal, entre otras.
WO2010002472A1 (en) * 2008-07-02 2010-01-07 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
FR2933982A1 (fr) * 2008-07-18 2010-01-22 Sanofi Aventis Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
UY32049A (es) * 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
CA2752105C (en) * 2009-02-13 2017-10-31 Matthias Vennemann Fused pyrimidines
LT2432472T (lt) 2009-05-22 2020-02-10 Incyte Holdings Corporation 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- arba heptan-nitrilas, kaip jak inhibitoriai
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
DK2448938T5 (en) 2009-06-29 2015-10-05 Incyte Corp Pyrimidinones AS PI3K inhibitors
WO2011018454A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
CU24167B1 (es) 2009-12-31 2016-03-31 Hutchison Medipharma Ltd Derivados de triazolopirazinas sustituidas como inhibidores del receptor c-met o hgf para tratar el cáncer
BR112012019302B1 (pt) 2010-02-03 2022-06-21 Incyte Holdings Corporation Imidazo[1,2-b] [1,2,4]triazinas como inibidores de c-met, composição que as compreende e métodos in vitro de inibir a atividade de c-met cinase, de inibir a via de sinalização da hgf/c-met cinase em uma célula e de inibir a atividade proliferativa de uma célula
CA2792508C (en) 2010-03-10 2018-01-16 Incyte Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US8518945B2 (en) * 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
EP2558468B1 (en) * 2010-04-14 2015-04-01 Array Biopharma, Inc. 5, 7-substituted-imidazo [1,2-c] pyrimidines as inhibitors of jak kinases
EA025281B9 (ru) 2010-05-17 2017-08-31 Инкозен Терапьютикс Пвт. Лтд. СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ
TWI499421B (zh) 2010-05-21 2015-09-11 Incyte Corp Ｊａｋ抑制劑的局部製劑
AU2011329734B2 (en) 2010-11-19 2015-05-28 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
AR084366A1 (es) 2010-12-20 2013-05-08 Incyte Corp N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
US9000186B2 (en) 2011-02-01 2015-04-07 Kyowa Hakko Kirin Co., Ltd. Ring-fused heterocyclic derivative
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
ES2560611T3 (es) 2011-06-20 2016-02-22 Incyte Holdings Corporation Derivados de fenil de azetidinilo, carboxamida de piridilo o pirazinilo como inhibidores de JAK
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
HRP20170285T1 (hr) 2011-09-02 2017-04-21 Incyte Holdings Corporation Heterociklilamini kao inhibitori pi3k
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US9062045B2 (en) 2011-09-15 2015-06-23 Novartis Ag Triazolopyridine compounds
CN103030654A (zh) * 2011-10-09 2013-04-10 济南赛文医药技术有限公司 一种小分子c-Met蛋白激酶抑制剂
JP2014528475A (ja) * 2011-10-12 2014-10-27 アレイ バイオファーマ、インコーポレイテッド ５，７置換イミダゾ［１，２−ｃ］ピリミジン
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
MX2014011987A (es) * 2012-04-03 2014-11-10 Novartis Ag Combinaciones de inhibidores de cinasa de tirosina y su uso.
MX371119B (es) 2012-04-03 2020-01-17 Novartis Ag Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
SI2861595T1 (sl) 2012-06-13 2017-04-26 Incyte Holdings Corporation Substituirane triciklične spojine kot inhibitorji fgfr
US20150216870A1 (en) * 2012-08-16 2015-08-06 Novartis Ag Combination of PI3K Inhibitor and C-Met Inhibitor
SG10202111768XA (en) 2012-11-15 2021-11-29 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
PE20200298A1 (es) 2013-03-06 2020-02-06 Incyte Holdings Corp Procesos e intermedios para hacer un inhibidor de jak
CN107312009B (zh) * 2013-04-17 2022-09-20 上海医药集团股份有限公司 喹啉类化合物、其制备方法、中间体、药物组合物和应用
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
CN114010611B (zh) 2013-08-07 2023-11-28 因赛特控股公司 Jak1抑制剂的持续释放剂型
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
GB201321732D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321736D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
RS59559B1 (sr) 2014-02-13 2019-12-31 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
PE20161384A1 (es) 2014-02-13 2016-12-28 Incyte Corp Ciclopropilaminas como inhibidores de lsd 1
WO2015123408A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
PH12016501545B1 (en) 2014-03-14 2023-12-06 Immutep Sas Antibody molecules to lag-3 and uses thereof
EP3848034B1 (en) 2014-03-26 2025-02-12 Astex Therapeutics Limited Cmet-inhibitors for use in delaying the emergence in resistance to fgfr inhibitors
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954840A1 (en) 2014-07-25 2016-01-28 Novartis Ag Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
MX373272B (es) * 2014-07-31 2020-04-16 Novartis Ag Terapia de combinacion.
CN107206071A (zh) 2014-09-13 2017-09-26 诺华股份有限公司 Alk抑制剂的联合疗法
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CA2964367C (en) 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
CA2976790C (en) * 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TWI713497B (zh) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
MX373232B (es) 2015-02-27 2020-05-08 Incyte Holdings Corp Sales del inhibidor fosfoinositida 3-cinasa (pi3k) y procesos para su preparación.
HK1248603A1 (zh) 2015-03-10 2018-10-19 Aduro Biotech, Inc. 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
TWI714567B (zh) 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
US10899764B2 (en) 2015-04-21 2021-01-26 Jiangsu Hengrui Medicine Co., Ltd. Imidazo isoindole derivative, preparation method therefor and medical use thereof
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US11420950B2 (en) 2015-05-22 2022-08-23 Chong Kun Dang Pharmaceutical Corp. Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
HUE070538T2 (hu) 2015-08-12 2025-06-28 Incyte Holdings Corp Egy LSD1 inhibitor sói
CA3007421A1 (en) * 2015-12-17 2017-06-22 Novartis Ag Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
KR102833068B1 (ko) 2015-12-17 2025-07-14 노파르티스 아게 Pd-1에 대한 항체 분자 및 그의 용도
EP3407886A1 (en) 2016-01-27 2018-12-05 Universität Zürich Use of gabaa receptor modulators for treatment of itch
LT3436461T (lt) * 2016-03-28 2024-03-12 Incyte Corporation Pirolotriazino junginiai kaip tam inhibitoriai
PE20190377A1 (es) 2016-04-22 2019-03-08 Incyte Corp Formulaciones de un inhibidor de lsd 1
EP3464267B1 (en) * 2016-05-23 2020-09-23 Boehringer Ingelheim International GmbH New phenylpyrazolylacetamide compounds and derivatives as cdk8/cdk19 inhibitors
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
CN106496000A (zh) * 2016-10-19 2017-03-15 蚌埠学院 一种3‑氟‑4‑溴‑苯乙酮的合成方法
MD3559009T2 (ro) 2016-12-22 2021-07-31 Calithera Biosciences Inc Compoziții și metode de inhibare a activității arginazei
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
MA49457A (fr) 2017-06-22 2020-04-29 Novartis Ag Molécules d'anticorps se liant à cd73 et leurs utilisations
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
CN111386273B (zh) 2017-09-27 2024-06-14 因赛特公司 可用作tam抑制剂的吡咯并三嗪衍生物的盐
KR102775718B1 (ko) * 2017-11-14 2025-03-06 칠드런'즈 메디컬 센터 코포레이션 인간 면역 반응을 조정하기 위한 이미다조피리미딘의 용도
KR102740831B1 (ko) 2017-11-14 2024-12-11 칠드런'즈 메디컬 센터 코포레이션 신규 이미다조피리미딘 화합물 및 그의 용도
BR112020008888A2 (pt) 2017-11-16 2020-10-20 Novartis Ag terapias de combinação
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
RS63312B1 (sr) 2018-01-30 2022-07-29 Incyte Corp Procesi za pripremu (1-(3-fluoro-2-(trifluorometil)izonikotinil)piperidin-4-on)
US12528810B2 (en) 2018-03-01 2026-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
MX2020010322A (es) 2018-03-30 2022-11-30 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
CN110526916B (zh) * 2018-05-23 2021-07-13 海创药业股份有限公司 氘代Capmatinib化合物及其用途
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
MX2020012826A (es) 2018-06-01 2021-03-09 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k).
CN108530337B (zh) * 2018-06-25 2020-11-03 南华大学 一种可选择性抑制胃癌细胞的吲哚酰胺类化合物
CN113164398B (zh) 2018-06-29 2023-11-03 因赛特公司 Axl/mer抑制剂的制剂
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
WO2020069418A1 (en) * 2018-09-28 2020-04-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk1/clk and uses thereof
TW202504901A (zh) * 2018-12-20 2025-02-01 美商英塞特公司 咪唑并嗒嗪及咪唑并吡啶化合物及其用途
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
SG11202106635WA (en) 2018-12-21 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate and kinase inhibitor
BR112021015672A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
US20220144807A1 (en) 2019-02-15 2022-05-12 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
CR20220285A (es) 2019-12-04 2022-10-27 Incyte Corp Derivados de un inhibidor de fgfr
EP4076660A1 (en) 2019-12-20 2022-10-26 Novartis AG Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
WO2021173476A1 (en) * 2020-02-24 2021-09-02 The Trustees Of Columbia University In The City Of New York Compounds, pharmaceutical formulations, and methods for treatment of cancer
WO2021178779A1 (en) 2020-03-06 2021-09-10 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN111825678A (zh) * 2020-06-05 2020-10-27 连庆泉 一种卡马替尼的制备方法
JP2023531676A (ja) 2020-06-23 2023-07-25 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
WO2022007752A1 (zh) * 2020-07-06 2022-01-13 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
JP2024532374A (ja) 2021-09-01 2024-09-05 ノバルティス アーゲー Ｔｅａｄ阻害剤を含む医薬品組み合わせ物及び癌の治療のためのその使用
CN113896732B (zh) * 2021-10-13 2023-09-12 沈阳红旗制药有限公司 抗癌药物卡马替尼的制备方法及其应用
WO2023249994A1 (en) * 2022-06-22 2023-12-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
KR20250044679A (ko) 2022-07-08 2025-04-01 아스트라제네카 아베 암 치료를 위한 hgf-수용체 억제제와 병용의 상피 성장 인자 수용체 티로신 키나아제 억제제
CN116903627B (zh) * 2023-05-15 2024-01-16 云白药征武科技(上海)有限公司 一种咪唑并三嗪硫代苯甲酰胺衍生物及其制备方法和应用

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1411859A (en) 1920-12-08 1922-04-04 Marchand Robert Process for preparing hydrate of terpin
US2837520A (en) * 1955-05-26 1958-06-03 Ind Chimica Profarmaco S R L Fluorescent materials on the basis of tetrazoindenes
US4209621A (en) * 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
US4405619A (en) * 1981-09-02 1983-09-20 Diamond Shamrock Corporation Antiinflammatory substituted-1,2,4-triazolo[4,3-b]-1,2,4-triazines
DE3311753A1 (de) 1983-03-31 1984-10-04 Hoechst Ag, 6230 Frankfurt Substituierte 6-aryl-1,2,4-triazolo(4,3-b)pyridazine - ihre herstellung und verwendung -
JPS6337347A (ja) 1986-08-01 1988-02-18 Fuji Photo Film Co Ltd 直接ポジカラ−画像形成方法
JPS63199347A (ja) 1987-02-14 1988-08-17 Konica Corp 鮮鋭性の向上した高感度ハロゲン化銀写真感光材料
JPS63310891A (ja) 1987-06-12 1988-12-19 Yoshitomi Pharmaceut Ind Ltd 縮合ピリダジン化合物
US5236917A (en) * 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
JPH0313934A (ja) 1989-06-12 1991-01-22 Konica Corp ハロゲン化銀写真感光材料
IL96432A0 (en) 1989-11-30 1991-08-16 Schering Ag Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives
JP2664264B2 (ja) 1990-02-15 1997-10-15 富士写真フイルム株式会社 ハロゲン化銀写真乳剤及びこれを用いた写真感光材料
FR2662163A1 (fr) 1990-05-16 1991-11-22 Lipha Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant.
JPH04251243A (ja) 1991-01-09 1992-09-07 Konica Corp ハロゲン化銀写真感光材料
FR2671551B1 (fr) * 1991-01-15 1993-03-12 Adir Nouveaux composes de structure aryl triazinique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5232618A (en) 1991-09-30 1993-08-03 E. I. Du Pont De Nemours And Company Substantially constant boiling compositions of difluoromethane and trifluoroethane or perfluoroethane
JPH05232618A (ja) 1992-02-21 1993-09-10 Konica Corp ハロゲン化銀写真感光材料
DE4309285A1 (de) 1993-03-23 1994-09-29 Boehringer Ingelheim Kg Heterocyclen enthaltende Amidinderivate, ihre Herstellung und Verwendung
SK179899A3 (en) 1997-07-03 2001-12-03 Du Pont Pharm Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
ES2137113B1 (es) 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
DE19734311A1 (de) 1997-08-08 1999-02-11 Bosch Gmbh Robert Anordnung zur Übertragung optischer Signale mit Ersatzschaltungswirkung
JP4251243B2 (ja) 1998-11-26 2009-04-08 株式会社日立メディコ 領域拡張装置
JP4025468B2 (ja) * 1999-07-29 2007-12-19 三井化学株式会社 有機電界発光素子
ATE288915T1 (de) 1999-11-10 2005-02-15 Ortho Mcneil Pharm Inc Substituierte 2-aryl-3-(heteroaryl)-imidazo(1,2- alpha)pyrimidine und ihren verwandten arzneimittel und verfahren
KR20020050262A (ko) 1999-11-12 2002-06-26 해피 페너 ; 해리 에이치. 페너 2세 비시클릭 및 트리시클릭 헤테로방향족 화합물
DE10010067A1 (de) * 2000-03-02 2001-09-06 Bayer Ag Neue Imidazotriazinone und ihre Verwendung
AU2000240570A1 (en) * 2000-03-29 2001-10-08 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
ATE310740T1 (de) 2000-11-10 2005-12-15 Merck Sharp & Dohme Imidazotriazin-derivate als liganden für gaba- rezeptoren
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
HRP20030719A2 (en) 2001-03-09 2005-04-30 Pfizer Products Inc. Triazolopyridines as anri-inflammatory agents
GB0107751D0 (en) 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
EP1396490A1 (en) 2001-05-24 2004-03-10 Yamanouchi Pharmaceutical Co. Ltd. 3-quinoline-2-(1h)-ylideneindolin-2-one derivatives
DE10130167A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
EP1481977A4 (en) * 2002-03-01 2006-02-01 Astellas Pharma Inc NITROGENIC HETEROCYCLIC COMPOUND
WO2003080621A1 (en) 2002-03-19 2003-10-02 Merck & Co., Inc. Process and intermediates to substituted imidazopyrimidines
US6790852B2 (en) 2002-04-18 2004-09-14 Hoffmann-La Roche Inc. 2-(2,6-dichlorophenyl)-diarylimidazoles
GB0210124D0 (en) * 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0210127D0 (en) * 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
DE10230605A1 (de) 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
WO2004020438A2 (en) 2002-08-30 2004-03-11 Pfizer Products Inc. Novel processes and intermediates for preparing triazolo-pyridines
US6784297B2 (en) 2002-09-04 2004-08-31 Kopran Limited Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate
RU2005122484A (ru) 2002-12-18 2006-01-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Композиции, используемые в качестве ингибиторов протеинкиназ
UA80171C2 (en) * 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
GB0303910D0 (en) * 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
JP4695588B2 (ja) 2003-02-26 2011-06-08 スージェン， インク． プロテインキナーゼ阻害剤としてのアミノヘテロアリール化合物
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
EP1640010A1 (en) 2003-07-01 2006-03-29 Astellas Pharma Inc. Agent inducing increase in bone mass
US20060009493A1 (en) 2003-07-02 2006-01-12 Sugen, Inc. Indolinone hydrazides as c-Met inhibitors
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
US7037909B2 (en) 2003-07-02 2006-05-02 Sugen, Inc. Tetracyclic compounds as c-Met inhibitors
MXPA06000091A (es) 2003-07-02 2006-04-07 Sugen Inc Arilmetiltriazolo e imidazopirazinas como inhibidores de c-met.
EP1660500B1 (en) 2003-07-30 2007-12-12 Laboratorios S.A.L.V.A.T., S.A. Substituted imidazopyrimidines for the prevention and treatment of cancer
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
EP1697352B1 (en) 2003-09-24 2012-06-27 Vertex Pharmceuticals Incorporated 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase
SI2392564T1 (sl) 2003-09-26 2014-02-28 Exelixis, Inc. c-Met modulatorji in postopki uporabe
US7144889B2 (en) * 2003-10-16 2006-12-05 Hoffman-La Roche Inc. Triarylimidazoles
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
CA2553423C (en) 2004-01-23 2012-03-20 Amgen Inc. Heterocyclic compounds for use in the treatment of cancer and the inhibition of angiogenesis
EP1711495A2 (en) 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
WO2005077953A1 (ja) 2004-02-18 2005-08-25 Banyu Pharmaceutical Co., Ltd. 含窒素縮合へテロ芳香環誘導体
CN1960993A (zh) * 2004-04-02 2007-05-09 Osi制药公司 6,6－双环取代的杂双环蛋白激酶抑制剂
US20050277650A1 (en) 2004-04-20 2005-12-15 Sundaram Venkataraman Process for preparing aripirazole hydrate
CA2564355C (en) 2004-05-07 2012-07-03 Amgen Inc. Protein kinase modulators and method of use
WO2005121125A1 (en) 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
EP1773826A4 (en) 2004-07-02 2009-06-03 Exelixis Inc MODULATORS OF C-MET AND THEIR METHOD OF USE
AR053090A1 (es) * 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
AU2005269386A1 (en) * 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
ME01788B (me) 2004-08-26 2011-02-28 Pfizer Enantiomerno čista aminoheteroaril jedinjenja kao inhibitori protein kinaza
EP1804801A2 (en) 2004-10-15 2007-07-11 Biogen Idec MA, Inc. Methods of treating vascular injuries
CA2586259A1 (en) * 2004-11-08 2006-05-11 Banyu Pharmaceutical Co., Ltd. Novel fused imidazole derivative
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
WO2006076575A2 (en) 2005-01-13 2006-07-20 Bristol-Myers Squibb Company Substituted biaryl compounds as factor xia inhibitors
US20090156617A1 (en) * 2005-05-12 2009-06-18 Northrup Alan B Tyrosine kinase inhibitors
WO2007008539A2 (en) 2005-07-11 2007-01-18 Smithkline Beecham Corporation Pyranopyridine compounds
WO2007015866A2 (en) * 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
CA2630884A1 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
MY159523A (en) 2005-12-21 2017-01-13 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
SI2495016T1 (sl) * 2005-12-23 2020-04-30 Ariad Pharmaceuticals, Inc. Biciklične heteroarilne spojine
WO2007096764A2 (en) * 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
PL2081937T3 (pl) 2006-10-23 2013-01-31 Sgx Pharmaceuticals Inc Triazolopirydazynowe modulatory kinaz białkowych
AU2007316417B2 (en) 2006-11-06 2013-08-22 Tolero Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
SI3034075T1 (sl) 2006-11-22 2018-12-31 Incyte Holdings Corporation Imidazotriazini in imidazopirimidini kot inhibitorji kinaze
CA2688823A1 (en) 2007-05-21 2008-11-27 Sgx Pharmaceuticals, Inc. Heterocyclic kinase modulators
CL2009001250A1 (es) * 2008-05-21 2010-02-05 Sal del acido dihidroclorico y dibencensulfonico de 2-fluoro-n-metil-4-[7-(quinolin-6-ilmetil)imidazol[1,2-b][1,2,4]1,2,4]triazin-2-il]benzamida; compuestos intermediarios; procesos de preparacion; composicion farmaceutica; y uso para tratar cancer, aterosclerosis, fibrosis pulmonar, enfermedad renal, entre otras.
BR112012019302B1 (pt) 2010-02-03 2022-06-21 Incyte Holdings Corporation Imidazo[1,2-b] [1,2,4]triazinas como inibidores de c-met, composição que as compreende e métodos in vitro de inibir a atividade de c-met cinase, de inibir a via de sinalização da hgf/c-met cinase em uma célula e de inibir a atividade proliferativa de uma célula
WO2012153684A1 (ja) 2011-05-06 2012-11-15 高砂香料工業株式会社 ルテニウム－ジアミン錯体および光学活性化合物の製造方法

Also Published As

Publication number Publication date
EP2497470A1 (en) 2012-09-12
NO20190709A1 (no) 2009-07-28
CA2669991A1 (en) 2008-05-29
NO2022057I1 (no) 2022-12-13
SI3034075T1 (sl) 2018-12-31
HK1225978B (en) 2017-09-22
CN101641093A (zh) 2010-02-03
EA032254B1 (ru) 2019-04-30
PT2099447E (pt) 2013-02-27
NO346024B1 (no) 2022-01-03
CY2022037I1 (el) 2023-01-27
PL3034075T3 (pl) 2019-03-29
NO344864B1 (no) 2020-06-02
IL284889B1 (en) 2023-01-01
EP3034075B1 (en) 2018-07-25
MX2009005144A (es) 2009-05-27
DK2497470T3 (en) 2015-12-07
SI2099447T1 (sl) 2013-03-29
MY188335A (en) 2021-11-30
NL301209I2 (nl) 2023-01-24
US20110136781A1 (en) 2011-06-09
EP2099447B1 (en) 2012-11-07
CN101641093B (zh) 2013-05-29
IL198716A0 (en) 2010-02-17
NO20200077A1 (no) 2009-07-28
CY1116763T1 (el) 2017-03-15
EP2497470B8 (en) 2015-12-02
LUC00293I2 (me) 2024-10-04
HRP20181622T1 (hr) 2018-12-14
ME02372B (me) 2016-06-20
BRPI0719333A2 (pt) 2014-02-04
HRP20130106T1 (hr) 2013-03-31
EA026126B1 (ru) 2017-03-31
ES2398843T3 (es) 2013-03-22
RS57741B1 (sr) 2018-12-31
US20130324515A1 (en) 2013-12-05
US7767675B2 (en) 2010-08-03
CY2022037I2 (el) 2023-03-24
PT3034075T (pt) 2018-11-05
GEP20125658B (en) 2012-10-10
IL284889A (en) 2021-08-31
NL301209I1 (nl) 2022-12-21
IL198716A (en) 2016-03-31
ECSP099400A (es) 2009-07-31
AU2007323725B2 (en) 2014-02-20
EP2099447A1 (en) 2009-09-16
US20250223291A1 (en) 2025-07-10
MY188338A (en) 2021-11-30
US20160326178A1 (en) 2016-11-10
LT3034075T (lt) 2018-11-26
EP3034075A1 (en) 2016-06-22
RS54510B1 (sr) 2016-06-30
ES2689444T3 (es) 2018-11-14
CY1117108T1 (el) 2017-04-05
PL2497470T3 (pl) 2016-04-29
LTC2099447I2 (me) 2025-04-25
ES2560435T3 (es) 2016-02-19
KR101532256B1 (ko) 2015-06-29
IL276928A (en) 2020-10-29
AR066142A1 (es) 2009-07-29
IL244244A0 (en) 2016-04-21
TWI429432B (zh) 2014-03-11
KR20090094299A (ko) 2009-09-04
IL284889B2 (en) 2023-05-01
NO20091924L (no) 2009-07-28
JP2010510319A (ja) 2010-04-02
US20230002392A1 (en) 2023-01-05
US12084449B2 (en) 2024-09-10
CA2669991C (en) 2016-01-26
HRP20160077T1 (hr) 2016-02-12
HUE026659T2 (en) 2016-07-28
CR10841A (es) 2009-06-30
US20180282340A1 (en) 2018-10-04
US20200317680A1 (en) 2020-10-08
NO344399B1 (no) 2019-11-25
RS52677B (sr) 2013-06-28
KR20150014476A (ko) 2015-02-06
US10738052B2 (en) 2020-08-11
SI2497470T1 (sl) 2016-02-29
NZ577127A (en) 2012-03-30
DK2099447T3 (da) 2013-02-18
WO2008064157A1 (en) 2008-05-29
PL2099447T3 (pl) 2013-06-28
CN103288833A (zh) 2013-09-11
KR101588583B1 (ko) 2016-01-28
EP2497470B1 (en) 2015-10-28
IL244244B (en) 2020-09-30
HK1136489A1 (en) 2010-07-02
US11261191B2 (en) 2022-03-01
FR22C1060I1 (fr) 2023-02-03
CL2007003341A1 (es) 2008-04-18
CO6210810A2 (es) 2010-10-20
HK1175700A1 (en) 2013-07-12
AU2007323725A1 (en) 2008-05-29
EA200970501A1 (ru) 2009-12-30
TW200835481A (en) 2008-09-01
US9944645B2 (en) 2018-04-17
US8461330B2 (en) 2013-06-11
IL276928B (en) 2022-03-01
FR22C1060I2 (fr) 2023-11-17
EA201691862A2 (ru) 2017-09-29
JP5572388B2 (ja) 2014-08-13
CN103288833B (zh) 2018-01-12
PT2497470E (pt) 2016-02-22
US20080167287A1 (en) 2008-07-10
HUS2200052I1 (hu) 2023-01-28
EA201691862A3 (ru) 2017-12-29
CY1121021T1 (el) 2020-05-29
EP3443958A1 (en) 2019-02-20
DK3034075T3 (en) 2018-10-22

Similar Documents

Publication Publication Date Title
ME01507B (me) Imidazotriazini i imidazopirimidini kao inhibitori kinaze
JP2010510319A5 (me)
HRP20231614T1 (hr) Spojevi pirolotriazina kao tam inhibitori
RU2012132426A (ru) ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗЫ
RU2011101901A (ru) Триазолопиридиновые соединения-ингибиторы jak и способы
JP2016510035A5 (me)
JP2016523911A5 (me)
JP2016522246A5 (me)
JP2017505794A5 (me)
RU2007102429A (ru) Производные пиримидиномочевины в качестве ингибиторов киназ
JP2019535664A5 (me)
SI2797918T1 (en) Bromodomain inhibitors
JP2019504901A5 (me)
RU2009101911A (ru) Производные пиридина и пиразина в качестве ингибиторов mnk-киназы
ME02856B (me) Aminopirimidinilni spojevi kao inhibitori jak
HRP20201469T1 (hr) Derivati tetrahidroizokinolina
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
US11529350B2 (en) Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
JP2013510876A5 (me)
RU2014120374A (ru) Имидазопиридазины
HRP20192151T1 (hr) Derivati izokromena kao inhibitori fosfoinozitid 3-kinaza
RU2014119254A (ru) Средства, вызывающие апоптоз, для лечения злокачественных новообразований и иммунных и аутоиммунных заболеваний
JP2009513575A5 (me)
JP2014530237A5 (me)
JP2009525978A5 (me)